A Differential Pharmacokinetic Analysis Of The Erythropoietin Receptor Population In Newborn And Adult Sheep.

P. Veng-Pedersen, S. Chapel, N.H. Al-Huniti, R.L. Schmidt, E.M. Sedars, R. J. Hohl, and J. A. Widness

The Colleges of Pharmacy (P.V.-P., N.H.A.-H.) and Medicine, Departments of Pediatrics (R.L.S., E.M.S., J.A.W.), and Internal Medicine (R.J.H.), The University of Iowa, Iowa City, Iowa.

Drug Metabolism and Pharmacokinetics, Aventis Pharmaceuticals, Bridgewater, New Jersey (S.C.).

Corresponding author: P. Veng-Pedersen
Address: College of Pharmacy, University of Iowa, Iowa City, IA 52242, USA
Phone: (319) 335-8792
Fax: (319) 335-9349
Email: veng@uiowa.edu

Number of text pages: 14
Number of tables: 1
Number of figures: 2
Number of references: 34 (max 40)
Number of words in the abstract: 245 (max 250)
Number of words in the introduction: 283 (max 750)
Number of words in the discussion: 1268 (max 1500)

Abbreviations:
Epo, erythropoietin; EpoR, erythropoietin receptor; r-HuEpo, recombinant human erythropoietin; PK, pharmacokinetics; TIM, tracer interaction method; IV, intravenous; BFU-E, burst forming units erythroids; CFU-E, colony forming units erythroids.
ABSTRACT

Strong evidence indicates that erythropoietin (Epo) is eliminated via Epo receptors (EpoR). Epo receptors may be classified as erythropoietic receptors that are largely located on erythroid progenitor cells in the bone marrow (BM), and non-erythropoietic receptors present in most tissues. Epo’s elimination kinetics was studied using a very sensitive tracer interaction method (TIM) before and after chemical ablation of BM as an indirect way of evaluating the EpoR through an assortment of PK parameters ($V_M, K_M, K, Cl$) used in differentiating the EpoR population in newborn and adult sheep. TIM identified a parallel nonlinear Michaelis-Menten ($V_M, K_M$), and linear ($K$) elimination pathway, and found the latter pathway to be significantly ($p<0.01$) more dominant in lamb: $K/(V_M/K_M+K)=0.309(25.3)$ vs. $0.0895(18.4)$ mean(cv%) lambs vs. adult sheep. The significantly ($p<0.01$) larger total clearance found for lambs indicates a larger non-hematopoietic tissue clearance of Epo ($Cl=118(10.9)$ ml/hr/kg vs. $67.8(19.3)$ lamb vs. adult sheep). The $V_M/K_M$ ratio for the nonlinear pathway was not found to be significantly different ($p>0.05$) between newborn and adults with values of $1.10(15.8)$ and $1.30(3.81) hr^{-1}$ respectively. We proposed the hypothesis that the linear pathway is via non-hematopoietic EpoR. Assuming that Epo’s elimination largely depends not only on erythropoietic EpoR, but also non-hematopoietic EpoR, this work shows a significant difference in the relative proportions of the two EpoR populations in lamb and adult sheep. The larger dominance of the non-hematopoietic EpoR in lamb support the hypothesis that these receptors are more needed in early life, e.g. providing neuroprotection from perinatal hypoxemic-ischemic episodes.
Erythropoietin (Epo) is a 34 kD glycoprotein hormone the primary function of which is to regulate erythrocyte production by stimulating the proliferation and differentiation of erythroid progenitors (Fisher, 2003). Epo exerts this effect by binding to specific cell-surface receptors (EpoR) on erythroid progenitor cells located primarily in the bone marrow (Sawada et al., 1990). In recent years EpoR have been identified in numerous non-hematopoietic tissues outside the bone marrow (Juul et al., 1998). An increasing number of recent reports have demonstrated and postulated Epo’s non-hematopoietic role in the development and protection of the central nervous system, and possibly other effects (Juul et al., 2001). The relative proportions and quantities of the erythropoietic and non-hematopoietic EpoRs in the body are not known in addition to how these quantities may change during development. Epo receptor mRNA analysis of isolated heterogeneous tissue samples provides only a microscopic local picture that cannot be extrapolated to consider the body as a whole. Also, gene expression does not always equate with protein expression. The objective of this study is to further our understanding of the EpoR population in-vivo. We present a pharmacokinetic (PK) analysis that looks at the macroscopic PK effect of the EpoRs in-vivo using a sensitive, tracer-based methodology, that we refer to as the tracer interaction method (TIM) (Veng-Pedersen et al., 1997). The TIM approach enables an in-vivo analysis of not only the quantity of EpoR’s, but also their binding characteristics. Since the latter differ among distinct receptor populations the TIM may be used to distinguish these populations. In the present study, we have combined the TIM methodology with chemical ablation of the EpoR population in the bone marrow to augment the differentiation of the EpoR population.
Animals

All procedures with animals received prior approval from the local University Animal Care and Use Committee. Animals were housed in an indoor, light- and temperature-controlled environment and were maintained in good health throughout the study period. Jugular venous catheters for blood sampling were surgically placed days before the first TIM study under pentobarbital anesthesia, and Ampicillin (1 g b.i.d.) was administered the first three postoperative days. Four adult sheep (weight = 23.8(11)kg), and four newborn sheep (6.45(15)kg) with post-natal ages from 8 to 9 days were used in the experiments. Each animal underwent two TIM experiments (Veng-Pedersen et al., 1997). The first TIM experiment was conducted before chemical ablation of the bone marrow with busulfan. The second TIM experiment was conducted 8-10 days following the start of the busulfan ablation. Thus, the analysis involved a total of 32 sets of plasma level data, namely 16 sets of 125 I-r-HuEpo tracer data, and 16 sets of “cold” r-HuEpo data. Each of the 16 tracer data sets consisted of approximately 36 plasma level vs. time data points, and each of the 16 “cold” data sets consisted of approximately 22 data points. Overall the analysis utilized approximately 930 plasma level data points.

Blood Level Assay

Plasma samples were assayed for 125 I-r-HuEpo using a sensitive and specific, double antibody, immunoprecipitation assay developed in our laboratory (Widness et al., 1992a) with a lower level of detection of 0.004 mU/ml. Plasma r-HuEpo concentration was measured in triplicate using a double-antibody radioimmunoassay (Widness et al., 1986). Linear assay values for r-HuEpo concentrations are obtained between 10 and 450 mU/ml in the sheep RIA. To reduce assay variability all samples were measured in
the same assay. To assess CFU-E and BFU-E, samples from the bone marrow before and after busulfan treatment were cultured as previously described (Clapp et al., 1995). Colonies derived from CFU-Es were counted after 6 days of incubation, while BFU-E colonies were counted after 9 days of incubation.

Study Protocol

Ablation by busulfan: busulfan was administered orally twice a day in a dose of 11 mg/kg/day for three consecutive days. Ampicillin (1 g b.i.d.) was administered daily for the first 3 days prior to the busulfan treatment, and again daily after the start of the treatment. Animals were clinically monitored for adverse effects of the chemotherapy such as weight loss, hair loss, blood in urine or stools, fever, unusual bleeding or bruising, and loss of appetite. TIM Experiments: a detailed description of the theory and principles of the TIM methodology has previously been published (Veng-Pedersen et al., 1997). Briefly, each TIM experiment consists of two stages: (a) An initial 0.10U/kg IV bolus dose of an 125 I-r-HuEpo tracer (specific activity 1.42x10^6 CPM/U) immediately followed by an IV infusion at 0.70 mU/kg/min of the tracer to the end of the experiment. (b) An IV bolus bolus of the r-HuEpo non-tracer administered at the plateau of the tracer (around 4 hours).

The immediate, abrupt rise in the plasma tracer level seen following the bolus dose of the r-HuEpo non-tracer, as seen in the upper panels of Figs 1 and 2, is a result of the nonlinear Epo elimination. Similarly, the absence of such a perturbation in the tracer level, as seen in the lower panels of Figs 1 and 2 following the BM ablation signifies a lack of nonlinearity, i.e. demonstrates linearity in the disposition kinetics.
Data Analysis

The tracer plasma level data were analyzed according to the TIM-based PK model given by Eq. 1 and 2 using the interactive WINFUNFIT computer program for general nonlinear regression, written for the Windows (Microsoft) platform, evolved from the original FUNFIT program (Veng-Pedersen, 1977).

\[
\frac{dc_a}{dt} = \left( K + \frac{V_m}{K_m + c_a} + \frac{G}{\gamma} \right) c_a + Ge^{-\gamma t} * c_a + \frac{R}{V} \quad \text{for} \quad 0 < t \leq T \quad \text{(Eq. 1)}
\]

\[
\frac{dc_a}{dt} = \left( K + \frac{V_m}{K_m + c_b} + \frac{G}{\gamma} \right) c_a + Ge^{-\gamma t} * c_a + \frac{R}{V} \quad \text{for} \quad t > T
\]

\[
\frac{dc_a}{dt} = -\left( K + \frac{G}{\gamma} \right) c_a + Ge^{-\gamma t} * c_a + \frac{R}{V} \quad \text{(Eq. 2)}
\]

The convolution type (∗ denotes convolution), integro-differential equations (Eqs 1 and 2) describe the tracer plasma level in the TIM experiments in the presence and absence of a nonlinear elimination pathway respectively, corresponding to the “before” and “after” ablation conditions. Equation 1 applied before the busulfan marrow ablation considers an elimination via two routes, namely a nonlinear route corresponding to the Michaelis-Menten terms \( V_m/(K_m + c_b) \) and \( V_m/(K_m + c_a) \), and a linear route corresponding to the 1st-order elimination rate constant \( K \). The terms \( c_a \) and \( c_b \) denote the plasma concentration profiles of the 125 I-r-HuEpo tracer and the “cold” r-HuEpo respectively. The rate of infusion of the tracer is denoted by \( R \) and the volume of distribution by \( V \). Equation 2, applied after the ablation, contains only the linear elimination pathway (\( K \)) remaining after the nonlinear pathway has been obliterated by the busulfan BM ablation. Equation 2 is the function used to describe the tracer data (curve fitted to square symbols) in the ablated state as shown in the lower panel of Figs. 1 and 2. Equation 2
is obtained from Eq. 1 by deleting the nonlinear terms $V_M/(K_M + c_a)$ and $V_M/(K_M + c_b)$ corresponding to the nonlinear elimination pathway. In the above equations $K_M$ and $V_M$ are the Michaelis-Menten parameters, G and g are distribution function parameters, and $T$ is the time when the I.V. bolus dose of the “cold” erythropoietin is injected (Veng-Pedersen et al., 1997).

Equations 1 and 2 are conveniently converted to the following equivalent equations (Eqs. 3-4). These new equations are simpler to deal with computationally because they do not involve a convolution operation. Equations 3-5 are ordinary first order differential equations (ODE) that in contrast to the original equations (Eqs. 1 and 2) can be solved numerically by regular ODE software.

$$
\frac{dc_a}{dt} = - \left( K + \frac{V_m}{K_m + c_a} + \frac{G}{\gamma} \right) c_a + z + R/V \quad \text{for} \quad 0 < t \leq T \quad \text{(Eq. 3)}
$$

$$
\frac{dc_a}{dt} = - \left( K + \frac{V_m}{K_m + c_b} + \frac{G}{\gamma} \right) c_a + z + R/V \quad \text{for} \quad t > T
$$

$$
\frac{dz}{dt} = - \gamma z + Gc_a \quad \text{z(0)} = 0 \quad \text{(Eq. 5)}
$$

The variable $z$ introduced in Eqs.3-5 is a dummy variable that has the exact same effect as the convolution term in Eqs1,2. Equations 3-5 were used in the curve fittings. A cross-validation cubic spline (Hutchinson and deHoog, 1985) fitted to the unlabeled r-HuEpo data was used to represent the “cold” r-HuEpo plasma concentration profile, $c_b$ in Eqs.3. The numerical integration solution, $c_a(t)$, of the two components of Eq. 3 is fitted using WINFUNFIT to the tracer data for the pre- ($t<T$) and post- ($t>T$) “cold” r-
HuEpo administration phases before the ablation. This fitting of Eq. 3 to the pre-ablation tracer data is done simultaneously with the fitting of Eq. 4 to the tracer data acquired after the complete ablation (occurring 8-10 days after busulfan treatment (Chapel et al., 2001)).

The clearance parameter (Cl) of drugs with nonlinear elimination kinetics is not a constant parameter, but is concentration dependent. However, a unique clearance parameter denoted the *linear clearance* is the clearance corresponding to “very small” concentrations of erythropoietin, defined as concentrations much smaller that the $K_M$ value, i.e. $c << K_M$ which gives $V_M/(K_M+c) = V_M/K_M$. Accordingly, the clearance (“linear clearance”) reported in this work (Table 1) is calculated as follows:

**Pre-ablation:**

$$ Cl = V(V_M/K_M + K) \quad (Eq. \ 6) $$

**Post-ablation:**

$$ Cl = VK \quad (Eq. \ 7) $$
RESULTS

The correlation coefficients between predicted (Eqs. 1 and 2) and observed Epo tracer concentrations were 0.994 and 0.991 for the newborn and adult data respectively, showing a good agreement with the data for the proposed TIM model.

Busulfan Ablation Effects

Effect on Elimination Kinetics: The ablation of the bone marrow by busulfan had a marked effect on the elimination kinetics of Epo as determined by the TIM experiments. This effect is clearly shown in the representative plots in Figs 1 and 2 where the upper panel (pre-ablation TIM data) shows a significant perturbation in the tracer data (square symbols) caused by the bolus injection of the non-tracer (+ symbol) at about 4 hr. The pronounced perturbation is absent in the lower panel in the ablated state. This phenomenon was consistently observed in all 8 animals. The finding that the bone marrow ablation changes the elimination kinetics from nonlinear to linear, corresponding to an elimination of the nonlinear elimination pathway (Eqs. 1 and 2), was further tested. This was done in the fully ablated state 9 days following the start of the busulfan treatment by two additional experiments using significantly larger bolus doses of the non-tracer r-HuEpo. In these experiments the standard r-HuEpo dose of 100 U/kg was increased to 400 U/kg and 4000 U/kg. Doing so did not result in a detectable perturbation in the tracer level (data not shown), further confirming the linear elimination kinetics in the ablated state. Nonlinearity may still exist at higher concentrations, however a dosing as high or higher than 4000 U/kg is not met in current clinically practice. Effect on Volume of Distribution (V): The volume of distribution was not found to change significantly (p>0.05) as a result of the ablation with before / after the ablation values mean(CV%) for newborns: 74.4(5.24) / 78.2(15.0) ml/kg, and for adults:
47.5(20.5) / 58.0(20.0) ml/kg, respectively. **Effect on Clearance (Cl):** The ablation resulted in a substantial reduction in the tracer clearance in both adult and newborn sheep (p<0.01, Table 1).

**Newborn Compared To Adult Sheep**

*Clearance (Cl) before ablation:* The newborn had a significantly (p<0.01) larger clearance before ablation than adults with Cl values of 118(10.9) and 67.8(19.8) ml/hr/kg, respectively (Table 1). *Clearance (Cl) after ablation:* The newborns also had a significantly (p<0.01) larger clearance after the ablation than adults with Cl values of 39.8(40.8) and 7.62(39.8) m/hr/kg, respectively (Table 1). *Reduction in clearance (Cl) resulting from the ablation:* With the reduction in clearance expressed in a relative manner as (Cl after ablation)/(Cl before ablation) the newborn showed a significantly smaller reduction resulting from the ablation (p<0.05) with values of 0.333(37.3) and 0.110(19.6) for newborn and adults, respectively. *First order elimination rate constant (K) for the non-ablated elimination pathway:* The elimination rate constant for the non-ablated elimination pathway was found to be significantly larger for the newborn than the adults with values of 0.498(33.2) and 0.128(17.9) hr$^{-1}$, respectively (Table 1). *“First order” elimination rate constant (V_M/K_M) for the ablated elimination pathway:* The first order elimination rate constant corresponding to low concentrations (c<<K_M) for the ablatable elimination pathway was not found to be significantly different between newborn and adults with values of 1.10(15.8) and 1.30(3.81) hr$^{-1}$ respectively (Table 1). *Michaelis-Menten parameter K_M:* The K_M parameter for the ablated elimination pathway was not found to be significantly different (p>0.05) between newborn and adults with values of 425(17) and 523(15) mU/ml respectively. The values are similar to reported

in-vitro binding affinity \( k_a \) values for humans and animal erythroid progenitors cell lines expressing EpoR, i.e. 240-2400 mU/ml (Sawyer, 1990)

The maximum plasma concentration of the tracer was consistently less that 4500 CPM/ml, which corresponds to about 3 mU/ml. Thus the tracer concentration, \( c_a \), was all the time well into to linear range (\( c_a < < K_m \)). Accordingly, the \( V_m/(K_m+c_a) \) term in Eq.3 \( t\leq T \) becomes \( V_m/K_m \) and the TIM analysis can as previously discussed (Veng-Pedersen et al., 1997) be done by measuring the tracer in CPM/ml units without the need for converting to mU/ml. This is a convenient advantage since an accurate determination of the specific activity of biologicals can be a problem.

**Michaelis-Menten parameter \( V_M \):** The \( V_M \) parameter for the ablated elimination pathway was not found to be significantly different (p>0.05) between newborn and adults with values of 455(34) and 682(24) mU/ml/h respectively.

**Relative dominance of the non-ablated elimination pathway \( K/(V_M/K_M+K) \):** The relative dominance of the non-ablated elimination pathway was found to be significantly larger for newborn than adults with values of 0.309(25.3) and 0.0895(18.4) respectively (Table 1).

**Ablation by busulfan:** No CFU-E colonies were found after 6 days of incubation for bone marrow aspirates drawn at day 8 and day 13 following busulfan treatment. In contrast, pre-busulfan aspirates yielded 29 CFU-E colonies per 105 cells in CFU-E cultures. Similarly, when those samples were incubated for 9 days, 29, 3 and 0 colonies/105 cells in BFU-E culture were observed for the samples drawn on day -1, 8 and 13, respectively. Microscopic analysis of bone marrow core biopsies showed no significant cellularity after the busulfan treatment.
DISCUSSION

Contrary to most non-protein type of drugs, the kidneys and liver are not considered important in the in vivo elimination of Epo (Widness et al., 1996; Yoon et al., 1997). Also, the long-term stability of Epo in whole blood at room temperature indicates that no significant biotransformation takes place in blood (Widness et al., 1984; Kendall et al., 1991). However, the possibility of a tissue-based, extra-renal, extra-hepatic elimination e.g. via proteolysis cannot be completely ruled out. An increasing amount of evidence suggests that the metabolic fate of Epo is largely depending on the bone marrow containing EpoR carrying progenitor cells that eliminate Epo through endocytosis of the EpoR-Epo complex followed by lysosomal degradation (Sawyer, 1990; Sawyer and Hankins, 1993; Fisher, 2003). The hypothesis of a receptor-based elimination is consistent with previous findings that most growth factors, neuropeptides and biologically active endogenous polypeptides are eliminated via receptor-based endocytosis (Gammeltoft, 1991).

Erythroid progenitor mass has been shown to be a determinant of serum Epo concentration at a given Hb level (Cazzola et al., 1998). Subjects infected with human parvovirus (B19) showed a severe loss of EpoR-carrying erythroid precursor cells resulting in a pronounced increase in the Epo plasma level that was nearly inversely related to the presence of red blood cell progenitors. It was suggested that this relationship reflects Epo’s binding to receptors (Potter et al., 1987). After observing that plasma Epo levels remained abnormally high in sublethally irradiating dogs following the cessation of hypoxia, Stohlman concluded that plasma Epo levels were significantly “influenced by the functional state of the erythroid tissue of the marrow” (Stohlman, 1959). Other studies have documented that plasma Epo levels increase following bone
marrow ablation in excess of that expected by a reduction in Hb alone (Grace et al., 1991; Davies et al., 1995). Several studies have reported nonlinearity in Epo’s PK in which its plasma clearance decreases with increasing Epo doses (Kato et al., 1997a; Yoon et al., 1997) consistent with a Michaelis-Menten-type elimination kinetics.

EPO’s nonlinear behavior has been documented in various animal species including rats (Kato et al., 1997b), mice (Kato et al., 1998), rabbits (Yoon et al., 1997), sheep (Veng-Pedersen et al., 1999), and humans (Flaharty et al., 1990; Veng-Pedersen et al., 1995; Veng-Pedersen et al., 1999).

The fact that the ablation of the bone marrow changes the elimination kinetics from nonlinear (linear+nonlinear) to purely linear (Eqs.1 and 2, Figs.1 and 2) supports the hypothesis that the nonlinear elimination kinetics is due to elimination via the EpoR pool located in the bone marrow. However, the possibility that the nonlinearity present before ablation is due to both a nonlinear and linear binding component of the EpoR in the bone marrow cannot be completely ruled out.

It is well recognized that EpoRs exist in many tissues other than the bone marrow (Juul et al., 2001; Nagai et al., 2001). The role of these non-hematopoietic receptors is not well understood. However, recent reports have indicated that at least some of these receptors appear to have a neuroprotective role in protection from hypoxemic-ischemic insults (Juul, 2002). Busulfan ablation is considerably more selective in ablating bone marrow cells than most other tissues cells in the body, including tissues where mRNA for EpoR have been detected (Carlini et al., 1999). Thus, it does not seem very likely that such EpoR cells outside the bone marrow will be much affected by the busulfan treatment.
The PK parameters obtained by the TIM analysis provides an indirect quantification of the EpoR populations under the well-supported assumption that Epo’s elimination is via EpoRs. From this assumption it follows from simple kinetic principles that the quantity of ablative EpoR is proportional to $V_M/K_M$ and the quantity of receptors remaining after the busulfan ablation is proportional to $K$. The total ablation of the bone marrow makes it possible to “isolate” the receptors outside the bone marrow. This is of particular interest considering the discovery of the neuroprotective role of Epo (Juul, 2002) and the recent attention to Epo’s possible non-hematopoietic importance in development.

Based on the analysis of the data from this study (Table 1) we propose the following Epo Receptor Development (ERD) hypothesis: The non-erythroid receptors are most dominant while playing an important role in early development. Their relative importance diminishes later in development when Epo’s role is more directed at ensuring proper tissue oxygenation by production of red blood cells.

The ERD hypothesis suggests that the observation that severe hypoxemic-ischemic episodes in the life of mammals occurring at birth, e.g. perinatal asphyxia. The effect of such episodes may be mitigated to a greater extent in newborn relative to adult (Dawes, 1968). As discussed below, our PK analysis supports this ERD hypothesis under the assumptions that: (a) a significant fraction of the receptors located outside BM is aimed at neuroprotection, and (b) Epo is primarily eliminated via its Epo receptors. With respect to assumption (a) we propose that the elimination of Epo after the bone marrow ablation is primarily via non-hematopoietic receptors, as quantified by the rate constant $K$.

Our PK analysis does not provide an analysis of the function(s) of the proposed non-hematopoietic EpoR population; we can only speculate that it involves receptors
associated with neuroprotective and other yet to be discovered effects. The large amount of evidence of Epo's elimination via erythropoietic EpoR in the bone marrow supports the hypothesis that non-erythropoietic Epo receptors outside the bone marrow are also involved in the elimination. Accordingly, the quantification of the elimination by $V_M/K_M$ in combination with $K$ (Table 1) gives a “reference” from which an indirect measure of the relative importance of the non-hematopoietic EpoR population can be obtained. This measure is given by $K/(V_M/K_M+K)$ (Table 1), which is the fraction of Epo that is eliminated via the non-hematopoietic pathway. This fraction is significantly ($p<0.05$) larger in the newborn than adult sheep, indicating that the linear elimination, i.e. the non-hematopoietic EpoR population, is more dominant in lamb than adult sheep.

The reduction in the total clearance expressed as the ratio $(Cl_{after\ ablation})/(Cl_{before\ ablation})$ also shows a significantly ($p<0.05$) smaller reduction for newborn (0.333(37.3) vs. 0.110(19.6)) again supporting the ERD hypothesis. Moreover, looking at the non-hematopoietic elimination pathway in an absolute, rather than relative sense, gives the same consistent picture: the value for $K$ is significantly ($p<0.05$) larger for the newborn compared to adult sheep. Our finding of a significantly ($p<0.05$) larger total clearance for the newborn in the non-ablated state compared to adult sheep is consistent with our earlier findings (Widness et al., 1992b). This may be explained by the more pronounced elimination via non-erythropoietic EpoR in newborn as evident by a smaller reduction in the total clearance by the BM ablation.

The use of a tracer in PK analysis is based on the assumption that the tracer behaves in an identical kinetic manner to that of the parent drug, which is never exactly the case. However, the difference is usually so small that the analysis results provide reliable useful information about the parent drug. In any case when analyzing the PK disposition
with an unknown endogenous production under dynamically variable conditions such as in the present study, there is no alternative to the use of a tracer.

It is difficult to predict if the current study extrapolates to humans. However, because Epo genetically is well preserved across mammalian species, and because of an excellent similarity in the PK between sheep and humans (Veng-Pedersen et al., 1999) we believe such an extrapolation is indeed possible, but the final answer will have to wait until a safe (non-radioactive) r-HuEpo tracer is developed enabling the ERD hypothesis to be tested in humans.
Acknowledgements

The recombinant human EPO used in the EPO RIA was a gift from Dr. H. Kinoshita of Chugai Pharmaceutical Company, Ltd. (Tokyo, Japan). The rabbit EPO antiserum used in the EPO RIA was a generous gift from Gisela K. Clemens, Ph.D. The authors gratefully acknowledge the technical advice on CFU-E cultures from Dr. Wade Clapp, Indiana University School of Medicine.
References


Dawes GS (1968) *Birth asphyxia resuscitation and brain damage*. Year Book Medical Publisher Inc, Chicago.


Footnotes

Address correspondence to: Dr Peter Veng-Persen, University of Iowa, College of Pharmacy, Iowa City, IA 52242. Email veng@uiowa.edu

This work is supported by the United States Public Health Service National Institute of Health Grants P01 HL46925, R21, GM57367 and Grant RR000359 from the General Clinical Research Center Program, National Center for Research Resources, National Institute of Health.
Figure 1. Tracer Interaction Method (TIM) experiment conducted in an adult sheep before and after busulfan treatment. The curves shown fitted simultaneously to the 125 I-r-HuEpo tracer data (squares) before and after busulfan treatment (top and bottom panels) are given by Eqs. 1-2. The non-tracer r-HuEpo data (+) are fitted by a general cross validation cubic spline function. The arrow indicates the time when r-HuEpo is injected.

Figure 2. Tracer Interaction Method (TIM) experiment conducted in a newborn sheep before and after busulfan treatment. The curves shown fitted simultaneously to the 125 I-r-HuEpo tracer data (squares) before and after busulfan treatment (top and bottom panels) are given by Eqs. 1 and 2. The non-tracer r-HuEpo data (crosses) are fitted by a general cross validation cubic spline function. The arrow indicates the time when r-HuEpo is injected.
Table 1. Pharmacokinetic parameters determined from simultaneous fitting of Eqs. 3 and 4 to plasma level data acquired before and after bone marrow ablation.

<table>
<thead>
<tr>
<th></th>
<th>( V_M/K_M ) (1/hr)</th>
<th>( K ) (1/hr)</th>
<th>( K ) ( V_M/K_M + K )</th>
<th>Cl (mL/hr/kg)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Pre-ablation</td>
<td>Post-ablation</td>
<td>Pre-ablation</td>
<td>Post-ablation</td>
</tr>
<tr>
<td>Newborn</td>
<td>Mean</td>
<td>1.10</td>
<td>0.498</td>
<td>0.309</td>
</tr>
<tr>
<td></td>
<td>CV%</td>
<td>15.8</td>
<td>33.2</td>
<td>25.3</td>
</tr>
<tr>
<td>Adult</td>
<td>Mean</td>
<td>1.30</td>
<td>0.128</td>
<td>0.0895</td>
</tr>
<tr>
<td></td>
<td>CV%</td>
<td>3.81</td>
<td>17.9</td>
<td>18.4</td>
</tr>
<tr>
<td>( H_0: ) Newborn = Adult:</td>
<td>p&gt;0.05</td>
<td>p&lt;0.05</td>
<td>p&lt;0.05</td>
<td>p&lt;0.01</td>
</tr>
<tr>
<td>( H_0: ) Cl before = Cl after:</td>
<td></td>
<td></td>
<td></td>
<td>p&lt;0.01</td>
</tr>
</tbody>
</table>
Figure 1

Plasma 125I-r-HuEPO (cpm/mL)

Hours

After Busulfan

Before Busulfan

Hours

+ Plasma r-HuEPO (mU/mL)
Figure 2

- Plasma 125I-r-HuEPO (cpm/mL)
- Plasma r-HuEPO (mU/mL)

After Busulfan

Before Busulfan

Hours

+ Plasma r-HuEPO (mU/mL)